Autologous peripheral blood stem cell transplantation as consolidation for high risk diffuse large B-cell lymphoma:A phase II study
Not Applicable
- Conditions
- Diffuse Large B-Cell Lymphoma:IPI high risk group, CR1
- Registration Number
- JPRN-UMIN000012546
- Lead Sponsor
- ishiwaki Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1.Drug allergy used for conditioning regimen. 2.Positive HBs antigen or seropositive to HIV.(Not exclude for seropositive to HCV) 3.Uncontrolled infection. 4.Patients inappropriate for transplantation with reasons other than above.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year disease-free survival and the treatment-related toxicity
- Secondary Outcome Measures
Name Time Method -Relapse rate within one year after the transplant -Non-relapse mortality rate within one-year after the transplant -1-year disease-free survival -2-year overall survival rate